WT
ALXN

Wilmington Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Wilmington Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$1.45M Sell
9,290
-367
-4% -$57.9K 0.02% 316
2014
Q1 		$1.47M Sell
9,657
-315
-3% -$50.1K 0.03% 301
2013
Q4 		$1.32M Buy
9,972
+524
+6% +$62.9K 0.02% 311
2013
Q3 		$1.1M Buy
9,448
+102
+1% +$11.2K 0.02% 325
2013
Q2 		$862K Buy
+9,346
New +$901K 0.02% 352

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wilmington Trust's ALXN Position: Q2 2014 in Review

Wilmington Trust reduced its Alexion Pharmaceuticals (ALXN) stake by 3.8% in Q2 2014, selling an estimated $57.9K and leaving 9,290 shares worth $1.45M. The position accounts for 0.02% of the portfolio, ranked #316.

Wilmington Trust first reported a position in ALXN in Q2 2013 and has held it in 5 quarters since. The position peaked at $1.47M in Q1 2014. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

  • Wilmington Trust held 9,290 shares of Alexion Pharmaceuticals worth $1.45M as of Q2 2014.
  • Wilmington Trust sold 367 Alexion Pharmaceuticals shares in Q2 2014, an estimated $57.9K.
  • Alexion Pharmaceuticals made up 0.02% of Wilmington Trust's portfolio in Q2 2014, its #316 holding.
  • Wilmington Trust first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 5 quarters since.
  • Wilmington Trust's Alexion Pharmaceuticals position peaked at $1.47M in Q1 2014.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on Wilmington Trust's 13F filing for Q2 2014, filed 13 Aug 2014.